White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

Adeno-associated viral (AAV) vectors are a promising method for delivering genes in vivo, but pre-existing neutralizing antibodies (NAb) to AAV proteins present a significant challenge. A thorough understanding of immunogenicity is necessary for effective gene therapies.

Dive deep into the cutting-edge iLite® AAV NAb Assay platform. This powerful tool assesses the neutralization of AAV antibodies and includes AAV production in the same system. It overcomes the challenges of the AAV production step and reduces the steps in cumbersome cell-based AAV NAb assessment assays. Learn how in this whitepaper available for download.

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

This comprehensive white paper delves into the intricacies of AAV immunogenicity.

- Gain insights into the challenges of analyzing AAV NAbs and their relevance.

- Learn about the robustness of the iLite NAb platform to determine AAV immunogenicity or capsid inhibition for a wide range of serotypes using an advanced functional and adaptable bioassay.

- Explore how our cell engineering expertise enables the customization of the NAb platform to suit any AAV vector or capsid, providing unparalleled support and flexibility.

Download the white paper today and take the first step towards harnessing the full potential of your AAV in gene therapy.

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

Please complete the form to access the white paper

Address

Visiting address